Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.

Navas T, Pfister TD, Colantonio S, Aziz A, Dieckman L, Saul RG, Kaczmarczyk J, Borgel S, Alcoser SY, Hollingshead MG, Lee YH, Bottaro DP, Hiltke T, Whiteley G, Takebe N, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH.

PLoS One. 2018 Jun 21;13(6):e0199361. doi: 10.1371/journal.pone.0199361. eCollection 2018.

2.

Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis.

Dull AB, Wilsker D, Hollingshead M, Mazcko C, Annunziata CM, LeBlanc AK, Doroshow JH, Kinders RJ, Parchment RE.

Oncotarget. 2018 Mar 30;9(24):17104-17116. doi: 10.18632/oncotarget.24936. eCollection 2018 Mar 30.

3.

Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors.

Srivastava AK, Hollingshead MG, Govindharajulu JP, Covey JM, Liston D, Simpson MA, Peggins JO, Bottaro DP, Wright JJ, Kinders RJ, Doroshow JH, Parchment RE.

Mol Cancer Ther. 2018 Mar;17(3):698-709. doi: 10.1158/1535-7163.MCT-17-0552. Epub 2018 Feb 14.

PMID:
29444985
4.

Posterior Vitreous Detachment and the Posterior Hyaloid Membrane.

Fincham GS, James S, Spickett C, Hollingshead M, Thrasivoulou C, Poulson AV, McNinch A, Richards A, Snead D, Limb GA, Snead MP.

Ophthalmology. 2018 Feb;125(2):227-236. doi: 10.1016/j.ophtha.2017.08.001. Epub 2017 Sep 1.

5.

The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.

Holbeck SL, Camalier R, Crowell JA, Govindharajulu JP, Hollingshead M, Anderson LW, Polley E, Rubinstein L, Srivastava A, Wilsker D, Collins JM, Doroshow JH.

Cancer Res. 2017 Jul 1;77(13):3564-3576. doi: 10.1158/0008-5472.CAN-17-0489. Epub 2017 Apr 26.

6.

Effective implementation of novel MET pharmacodynamic assays in translational studies.

Srivastava AK, Navas T, Herrick WG, Hollingshead MG, Bottaro DP, Doroshow JH, Parchment RE.

Ann Transl Med. 2017 Jan;5(1):3. doi: 10.21037/atm.2016.12.78. Review.

7.

Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay.

Ji J, Zhang Y, Redon CE, Reinhold WC, Chen AP, Fogli LK, Holbeck SL, Parchment RE, Hollingshead M, Tomaszewski JE, Dudon Q, Pommier Y, Doroshow JH, Bonner WM.

PLoS One. 2017 Feb 3;12(2):e0171582. doi: 10.1371/journal.pone.0171582. eCollection 2017.

8.

Dual oxidase 2 and pancreatic adenocarcinoma: IFN-γ-mediated dual oxidase 2 overexpression results in H2O2-induced, ERK-associated up-regulation of HIF-1α and VEGF-A.

Wu Y, Meitzler JL, Antony S, Juhasz A, Lu J, Jiang G, Liu H, Hollingshead M, Haines DC, Butcher D, Panter MS, Roy K, Doroshow JH.

Oncotarget. 2016 Oct 18;7(42):68412-68433. doi: 10.18632/oncotarget.12032.

9.

Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.

Srivastava AK, Hollingshead MG, Weiner J, Navas T, Evrard YA, Khin SA, Ji JJ, Zhang Y, Borgel S, Pfister TD, Kinders RJ, Bottaro DP, Linehan WM, Tomaszewski JE, Doroshow JH, Parchment RE.

Clin Cancer Res. 2016 Jul 15;22(14):3683-94. doi: 10.1158/1078-0432.CCR-15-2323. Epub 2016 Mar 21.

10.

Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.

Srivastava AK, Jaganathan S, Stephen L, Hollingshead MG, Layhee A, Damour E, Govindharajulu JP, Donohue J, Esposito D, Mapes JP, Kinders RJ, Takebe N, Tomaszewski JE, Kummar S, Doroshow JH, Parchment RE.

Clin Cancer Res. 2016 Feb 15;22(4):1000-10. doi: 10.1158/1078-0432.CCR-14-3156. Epub 2015 Oct 7.

11.

"Glowing head" mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts.

Day CP, Carter J, Weaver Ohler Z, Bonomi C, El Meskini R, Martin P, Graff-Cherry C, Feigenbaum L, Tüting T, Van Dyke T, Hollingshead M, Merlino G.

PLoS One. 2014 Nov 4;9(11):e109956. doi: 10.1371/journal.pone.0109956. eCollection 2014.

12.

A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.

Figg WD, Monga M, Headlee D, Shah A, Chau CH, Peer C, Messman R, Elsayed YA, Murgo AJ, Melillo G, Ryan QC, Kalnitskiy M, Senderowicz AM, Hollingshead M, Arbuck SG, Sausville EA.

Cancer Chemother Pharmacol. 2014 Nov;74(5):955-67. doi: 10.1007/s00280-014-2569-7. Epub 2014 Sep 3.

PMID:
25183650
13.

Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4'-thio-2'-deoxycytidine and 5-aza-4'-thio-2'-deoxycytidine.

Thottassery JV, Sambandam V, Allan PW, Maddry JA, Maxuitenko YY, Tiwari K, Hollingshead M, Parker WB.

Cancer Chemother Pharmacol. 2014 Aug;74(2):291-302. doi: 10.1007/s00280-014-2503-z. Epub 2014 Jun 8.

14.

Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages--strategies for data mining in support of therapeutic studies.

Hollingshead MG, Stockwin LH, Alcoser SY, Newton DL, Orsburn BC, Bonomi CA, Borgel SD, Divelbiss R, Dougherty KM, Hager EJ, Holbeck SL, Kaur G, Kimmel DJ, Kunkel MW, Millione A, Mullendore ME, Stotler H, Collins J.

BMC Genomics. 2014 May 22;15:393. doi: 10.1186/1471-2164-15-393.

15.

Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues.

Park SR, Kinders RJ, Khin S, Hollingshead M, Antony S, Parchment RE, Tomaszewski JE, Kummar S, Doroshow JH.

Anal Biochem. 2014 Aug 15;459:1-11. doi: 10.1016/j.ab.2014.04.025. Epub 2014 May 4.

16.

Oxyphenisatin acetate (NSC 59687) triggers a cell starvation response leading to autophagy, mitochondrial dysfunction, and autocrine TNFα-mediated apoptosis.

Morrison BL, Mullendore ME, Stockwin LH, Borgel S, Hollingshead MG, Newton DL.

Cancer Med. 2013 Oct;2(5):687-700. doi: 10.1002/cam4.107. Epub 2013 Jul 23.

17.

A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept.

Mertins SD, Scudiero DA, Hollingshead MG, Divelbiss RD Jr, Alley MC, Monks A, Covell DG, Hite KM, Salomon DS, Niederhuber JE.

PLoS One. 2013;8(2):e57099. doi: 10.1371/journal.pone.0057099. Epub 2013 Feb 21.

18.

Activation of TLR4 is required for the synergistic induction of dual oxidase 2 and dual oxidase A2 by IFN-γ and lipopolysaccharide in human pancreatic cancer cell lines.

Wu Y, Lu J, Antony S, Juhasz A, Liu H, Jiang G, Meitzler JL, Hollingshead M, Haines DC, Butcher D, Roy K, Doroshow JH.

J Immunol. 2013 Feb 15;190(4):1859-72. doi: 10.4049/jimmunol.1201725. Epub 2013 Jan 7.

19.

Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.

Pfister TD, Hollingshead M, Kinders RJ, Zhang Y, Evrard YA, Ji J, Khin SA, Borgel S, Stotler H, Carter J, Divelbiss R, Kummar S, Pommier Y, Parchment RE, Tomaszewski JE, Doroshow JH.

PLoS One. 2012;7(12):e50494. doi: 10.1371/journal.pone.0050494. Epub 2012 Dec 28.

20.

Global metabolomics reveals urinary biomarkers of breast cancer in a mcf-7 xenograft mouse model.

Johnson CH, Manna SK, Krausz KW, Bonzo JA, Divelbiss RD, Hollingshead MG, Gonzalez FJ.

Metabolites. 2013 Aug 7;3(3):658-72. doi: 10.3390/metabo3030658.

21.

Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma.

Saini V, Hose CD, Monks A, Nagashima K, Han B, Newton DL, Millione A, Shah J, Hollingshead MG, Hite KM, Burkett MW, Delosh RM, Silvers TE, Scudiero DA, Shoemaker RH.

PLoS One. 2012;7(8):e41401. doi: 10.1371/journal.pone.0041401. Epub 2012 Aug 3. Erratum in: PLoS One. 2012;7(11). doi:10.1371/annotation/8c74aaee-897d-4682-b62d-d95a3506c210.

22.

Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.

Bennett CN, Tomlinson CC, Michalowski AM, Chu IM, Luger D, Mittereder LR, Aprelikova O, Shou J, Piwinica-Worms H, Caplen NJ, Hollingshead MG, Green JE.

Breast Cancer Res. 2012 Jul 19;14(4):R109. doi: 10.1186/bcr3230.

23.

DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer.

Chen M, Shabashvili D, Nawab A, Yang SX, Dyer LM, Brown KD, Hollingshead M, Hunter KW, Kaye FJ, Hochwald SN, Marquez VE, Steeg P, Zajac-Kaye M.

Mol Cancer Ther. 2012 Feb;11(2):370-82. doi: 10.1158/1535-7163.MCT-11-0458. Epub 2011 Dec 27.

24.

Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts.

Alcoser SY, Kimmel DJ, Borgel SD, Carter JP, Dougherty KM, Hollingshead MG.

BMC Biotechnol. 2011 Dec 16;11:124. doi: 10.1186/1472-6750-11-124.

25.

Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition.

Guo W, Wu S, Wang L, Wei X, Liu X, Wang J, Lu Z, Hollingshead M, Fang B.

PLoS One. 2011;6(12):e28487. doi: 10.1371/journal.pone.0028487. Epub 2011 Dec 12.

26.

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE, Doroshow JH.

Cancer Res. 2011 Sep 1;71(17):5626-34. doi: 10.1158/0008-5472.CAN-11-1227. Epub 2011 Jul 27.

27.

ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma.

Kenney S, Vistica DT, Stockwin LH, Burkett S, Hollingshead MG, Borgel SD, Butcher DO, Schrump DS, Shoemaker RH.

J Pediatr Hematol Oncol. 2011 Jul;33(5):360-8. doi: 10.1097/MPH.0b013e3182002f9f.

PMID:
21552147
28.

Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin.

Day CP, Carter J, Bonomi C, Hollingshead M, Merlino G.

Int J Cancer. 2012 Jan 1;130(1):190-9. doi: 10.1002/ijc.25978. Epub 2011 Apr 20.

29.

A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo.

Hancock CN, Stockwin LH, Han B, Divelbiss RD, Jun JH, Malhotra SV, Hollingshead MG, Newton DL.

Free Radic Biol Med. 2011 Jan 1;50(1):110-21. doi: 10.1016/j.freeradbiomed.2010.10.696. Epub 2010 Nov 4.

30.

Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.

Kinders RJ, Hollingshead M, Lawrence S, Ji J, Tabb B, Bonner WM, Pommier Y, Rubinstein L, Evrard YA, Parchment RE, Tomaszewski J, Doroshow JH; National Cancer Institute Phase 0 Clinical Trials Team.

Clin Cancer Res. 2010 Nov 15;16(22):5447-57. doi: 10.1158/1078-0432.CCR-09-3076. Epub 2010 Oct 5.

31.

Effect of a multifaceted, church-based wellness program on metabolic syndrome in 41 overweight or obese congregants.

Ivester P, Sergeant S, Danhauer SC, Case LD, Lamb A, Chilton BG, Delar B, Hollingshead ML, Weaver KL, Chilton FH.

Prev Chronic Dis. 2010 Jul;7(4):A81. Epub 2010 Jun 15.

32.

Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC.

Stockwin LH, Yu SX, Borgel S, Hancock C, Wolfe TL, Phillips LR, Hollingshead MG, Newton DL.

Int J Cancer. 2010 Dec 1;127(11):2510-9. doi: 10.1002/ijc.25499.

33.

Proteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor.

Han B, Stockwin LH, Hancock C, Yu SX, Hollingshead MG, Newton DL.

J Proteome Res. 2010 Aug 6;9(8):4016-27. doi: 10.1021/pr100194d. Erratum in: J Proteome Res. 2011 Apr 1;10(4):2128.

34.

Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel.

Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, Burkett MW, Hite KM, Alley M, Hollingshead M, Shoemaker RH, Niederhuber JE.

Stem Cells. 2010 Apr;28(4):649-60. doi: 10.1002/stem.324.

35.

Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.

Vistica DT, Hollingshead M, Borgel SD, Kenney S, Stockwin LH, Raffeld M, Schrump DS, Burkett S, Stone G, Butcher DO, Shoemaker RH.

J Pediatr Hematol Oncol. 2009 Aug;31(8):561-70. doi: 10.1097/MPH.0b013e3181a6e043.

36.

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.

Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH, Melillo G.

Mol Cancer Ther. 2009 Jul;8(7):1867-77. doi: 10.1158/1535-7163.MCT-09-0274. Epub 2009 Jul 7.

37.

Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction.

Stockwin LH, Han B, Yu SX, Hollingshead MG, ElSohly MA, Gul W, Slade D, Galal AM, Newton DL, Bumke MA.

Int J Cancer. 2009 Sep 15;125(6):1266-75. doi: 10.1002/ijc.24496. Erratum in: Int J Cancer. 2010 Dec;127(11):E1. Bumke, Maja A [added].

38.

ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC.

Stockwin LH, Yu SX, Stotler H, Hollingshead MG, Newton DL.

BMC Cancer. 2009 Feb 20;9:63. doi: 10.1186/1471-2407-9-63.

39.

Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study.

Day CP, Carter J, Bonomi C, Esposito D, Crise B, Ortiz-Conde B, Hollingshead M, Merlino G.

Pigment Cell Melanoma Res. 2009 Jun;22(3):283-95. doi: 10.1111/j.1755-148X.2009.00545.x. Epub 2009 Jan 19.

40.

Synthesis and evaluation of dihydroartemisinin and dihydroartemisitene acetal dimers showing anticancer and antiprotozoal activity.

Galal AM, Gul W, Slade D, Ross SA, Feng S, Hollingshead MG, Alley MC, Kaur G, ElSohly MA.

Bioorg Med Chem. 2009 Jan 15;17(2):741-51. doi: 10.1016/j.bmc.2008.11.050. Epub 2008 Nov 25.

PMID:
19084416
41.

Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.

Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, Parchment RE; National Cancer Institute Phase 0 Clinical Trials Team.

Clin Cancer Res. 2008 Nov 1;14(21):6877-85. doi: 10.1158/1078-0432.CCR-08-0214.

42.

Antitumor efficacy testing in rodents.

Hollingshead MG.

J Natl Cancer Inst. 2008 Nov 5;100(21):1500-10. doi: 10.1093/jnci/djn351. Epub 2008 Oct 28.

43.

CT and MR imaging of progressive dural involvement by nephrogenic systemic fibrosis.

Zelasko S, Hollingshead M, Castillo M, Bouldin TW.

AJNR Am J Neuroradiol. 2008 Nov;29(10):1880-2. doi: 10.3174/ajnr.A1225. Epub 2008 Oct 14.

44.

Designing phase 0 cancer clinical trials.

Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji J, Steinberg SM, Yang SX, Hollingshead M, Chen A, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.

Clin Cancer Res. 2008 Jun 15;14(12):3675-82. doi: 10.1158/1078-0432.CCR-07-4560.

45.

Phase 0 clinical trials: conceptions and misconceptions.

Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral OK, Simpson M, Hollingshead M, Yang SX, Helman L, Wiltrout R, Collins J, Tomaszewski JE, Doroshow JH.

Cancer J. 2008 May-Jun;14(3):133-7. doi: 10.1097/PPO.0b013e318172d6f3. Review.

PMID:
18536551
46.

Acute necrotizing encephalopathy of childhood: typical findings in an atypical disease.

Skelton BW, Hollingshead MC, Sledd AT, Phillips CD, Castillo M.

Pediatr Radiol. 2008 Jul;38(7):810-3. doi: 10.1007/s00247-008-0823-z. Epub 2008 Apr 16.

PMID:
18415059
47.

Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.

Wright MH, Robles AI, Herschkowitz JI, Hollingshead MG, Anver MR, Perou CM, Varticovski L.

Mol Cancer. 2008 Apr 7;7:29. doi: 10.1186/1476-4598-7-29.

48.

Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.

Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH.

Mol Interv. 2007 Dec;7(6):325-34. doi: 10.1124/mi.7.6.9. Review.

PMID:
18199854
49.

Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.

Memmott RM, Gills JJ, Hollingshead M, Powers MC, Chen Z, Kemp B, Kozikowski A, Dennis PA.

Cancer Res. 2008 Jan 15;68(2):580-8. doi: 10.1158/0008-5472.CAN-07-3091.

50.

Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts.

Papadopoulou MV, Bloomer WD, Taylor AP, Hernandez M, Blumenthal RD, Hollingshead MG.

Radiat Res. 2007 Jul;168(1):65-71.

PMID:
17722994

Supplemental Content

Loading ...
Support Center